Patent · US Active

Use of IL-1 β binding antibodies for treating peripheral arterial disease

US10000565B2 · kind B2 · utility

0Cited by

0References

15Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Craig Basson · Needham, US
Mark C. Fishman · Newton, US
Tom Thuren · Succasunna, US
Shi Yin Foo · Boston, US

Key dates

Filing date	Nov 14, 2013
Grant date	Jun 19, 2018
Priority date	—
Expiry date	Nov 14, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a method for treating or alleviating the symptoms of peripheral arterial disease (PAD) in a subject, comprising administering about 25 mg to about 300 mg of an IL-1β binding antibody or functional fragment thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.